Zoomind FAQ

Both Vayarin and Zoom were discontinued. We re-formulated this effective, natural ADHD supplement with the same ingredients as Zoom and Vayarin.

Recommended Dosage: 2 capsules per day or as directed by health care provider.
Capsules can be opened and sprinkled on food.

Remember, Zoomind is not a drug, so you won’t see effects instantly. Because Zoomind is a key building block, it takes time for the blocks to build up in your child’s brain. Zoomind can take up to 90 days to build up to the right level based on your child’s unique system, though some report a change as soon as 14 days.

If your child is currently taking ADHD drugs, talk to your provider about whether Zoomind is right for your child. No interactions with ADHD medications have been reported.

In a double blind placebo-controlled study, Vayarin® (same ingredients as Zoomind and Zoom) has been clinically shown to help reduce restlessness, hyperactivity, impulsivity, and inattention.

In a study with parents and teachers of ADHD children, Vayarin® (same ingredients as Zoomind) has also been shown to improve quality of life.

Results have been published in peer-reviewed journals like the American Journal of Clinical Nutrition and European Psychiatry.

  • Improves Quality of Life
  • Reduces Hyperactivity, Restlessness, Impulsivity and Inattention
  • Safe and Well-Tolerated

The adverse events of Vayarin® were evaluated in a randomized, double blind, placebo-controlled study of 15 weeks followed by an open label extension of an additional 15 weeks [38].

Adverse events reported during the course of the double-blind phase (table 2): 12 participants from the Vayarin® group and 5 participants from the placebo group were classified by the study physicians as suffering from treatment related, or probably related, adverse events (13 and 5 adverse events, respectively). There were no significant differences between the study groups in either the incidence or number of adverse events recorded (P = 0.848 and P = 0.982, respectively).

Adverse events reported during the course of the open-label extension: 5 participants reported 7 adverse events that were classified by the study physicians as related or probably related to the study treatment.

Zoomind, natural ADHD supplement capsules do not contain sugar, lactose, yeast, or gluten.

Phosphatidylserine (PS), Hydroxypropyl methylcellulose, Silicon dioxide, Contains less than 1% of Mixed tocopherols (D-alpha-tocopherol, D-betatocopherol, D-gamma-tocopherol, D-delta-tocopherol), Sunflower oil, Ascorbyl palmitate, Rosemary extract (Rosemary leaf, Propylene glycol, Distilled monoglycerides) (preservative), Caramel (color), Titanium dioxide (color). Zoomind capsules contain shellfish (Krill).

Zoomind may contain soy and fish. Zoomind is kosher.


Mechanism Of Action
Omega-3 long-chain polyunsaturated fatty acids (LC-PUFA) have an important role in brain and central nervous system development and functioning. Decreased omega-3 fatty acids levels, mainly DHA and EPA, are associated with the occurrence of psychiatric, neurodegenerative, and other neurodevelopmental disorders such as dyspraxia, dyslexia, autism, peroxisomal disorders5, Alzheimer’s disease6, and ADHD3, Administration of phosphatidylserine {PS} enriched with omega-3 fatty acids was found to significantly increase DHA level in rat brains.

While the exact mechanism by which Vayarin® exerts its effects is not fully understood, PS present in the mammalian nervous system, which is characterized by its substantial levels of omega-3 fatty acids, has been implicated in numerous membrane related functions, such as maintaining the integrity of cell membranes, cell excitability, cell-to-cell recognition and communication8. PS has been found to regulate key proteins in neuronal membranes, including sodium/calcium ATPase9 and protein kinase C10 which undertake crucial functions in diverse signal transduction pathways. Similarly, PS interacts with Raf-1 protein kinase to promote a cascade of reactions that are believed to be involved in cell survival. Additionally, PS has been found to influence neurotransmitter activity, such as the release of acetylcholine, dopamine and noradrenaline and to increase brain glucose levels.

Shipping is expected within 1-3 days of purchase within the United States.  

Ask A Question

Ask A Question


  1. Richardson, A.J., 0meqa-3 fatty acids in ADHD and related neu rod eve I op mental disorders. Irrt Rev Psychiatry, 2006. 13(2): p. 15W2.
  2. SanGiovanni, J.P., et al., Meta-analysis of dietary essential fatly acids and long-chain polyunsaturated fatty acids as they relate to visual resolution acuity in healthy preterm infants. Pediatrics, 2000.105(6): p. 1292-8.
  3. Schuchardt, J.P., et al., Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children. Eur J Pediatr, 2010.169(2): p. 149-64.
  4. Kawashima, A., et al., Effects of eicosapentaenoic acid on synaptic plasticity. fatty acid profile and phosphoiinositide 3-kinase signaling in rat hippocampus and differentiated PC12 cells. J Nutr Biochern, 2010.21(4): p. 268-77.
  5. Martinez, M.„ Severe deficiency of docosahexaenoic acid in Beroxisomal disorders: a defect of delta 4 desaturation? eurology, 1990. 40(8): p. 1292-8.
  6. Soderberg, M., et al., Fatty acid composition of brain phospholipids in aqinq and in Alzheimer’s disease. Lipids, 1991.26(6): p. 421-5.
  7. Vaisman, N., Pelled, D., n-3 phosphatidyl serine attenuated scopolamine-induced amnesia in middle-aged rats. Prog Neuropsychopharmacol Biol Psychiatry, 2009.33(6): p. 952-9..
  8. Mozzi, R., Buratta, S., Goracci, G., Metabolism and functions of phosphatidylserine in mammalian brain. Neurochem Res, 2003. 28(2): p. 195-214.
  9. Wheeler, R.P.W., R., ATPase activity of the sodium pump needs of phosphatidylserine. Nature, 1970. 225(5231): p. 449-450.
  10. Bittova, L., Stahelin, R.V., Cho, W., Roles of ionic residues of the C1 domain in protein kinase C-alpha activation and the origin of phosphatidylserine specificity. J Biol Ghem. 2001. 276(6): p. 4218-26.
  11. Vance, J.E., Phosphatidylserine and Phosphatidylethanolamine in Mammalian Cells: Two Metabolically-related Aminophospholipids. ASBMB, 2008: p. 1-48.
  12. Pepeu, G., Pepeu, I.M.,Amaducci, L., A review of phosphatidylserine pharmacological and clinical effects. Is phosphatidylserine a drug for the ageing brain? Pharmacol Res, 1996.33(2): p. 73-80.
  13. Mazzari, S. and A. Battistella, Phosphatidylserine effects on dopamine release from striatum synaptosomes. In: Multidisciplinary Approach to Brain Development. Elsevier North Holland Amsterdam, 1980: p. 569-570.
  14. Tso, P., Intestinal lipid absorption. Physiology of the gastrointestinal tract, ed. L.R. Johnson. Vol. 56.1994, New York: Raven Press.
  15. Wise, E.M., Elwyn, D., Rates of reactions involved in phosphatide synthesis in liver and small intestine of intact rats. Journal of Biological Chemistry, 1965. 240: p. 1537-1548.
  16. Heywood, R., Cozens, D., Richold, M., Toxicology of a phosphatidylserine preparation from bovine brain. C. Trials Journal, 1987.24(1): p. 25-32.
  17. Manor, I. et al., The effect of phosphatidylserine containing omega-3 fatty-acids on attentiion-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. Eur Psychiatry, 2012.27(5): p.335-42.
  18. Manor, I. et al., Safety of phosphatidylserine containing omega-3 fatty acids in ADHD children: A double-blind placebo-controlled trial followed by an open-label extension. Eur Psychiatry, 2013. Eur Psychiatry, 2013. 28(6):p. 386-91.

Read more in our blog

What’s New in ADHD

Two items appeared in the health-related journals over the past couple of weeks that combined serve up some very interesting food for thought that anyone interested in ADHD and how...

Mental Health Awareness Month

In many parts of the world, May is designated as the Mental Health Awareness Month, with a focus on raising the general levels of discussion and debate about mental health...